NEUROMARK
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NEUROMARK - overview
Location
Braintree, MA, US
Primary Industry
Medical Devices & Equipment
About
Based in Ireland, Neurent Medical Ltd. develops innovative treatment solutions for chronic rhinitis, specializing in the NEUROMARK® System that uses radiofrequency technology to alleviate nasal symptoms. Neurent Medical Ltd. is a medical technology company that focuses on chronic rhinitis treatment solutions.
Neurent Medical Ltd. is a medical technology company that focuses on chronic rhinitis treatment solutions. Based in Galway, Ireland, Neurent Medical was co-founded by Brian Shields and as of 2026 he is serving as CEO. In February 2026, Neurent Medical Ltd.
raised EUR 62. 5 million in series C funding led by MVM Partners, with participation from Sofinnova Partners, EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland. Neurent Medical specializes in the NEUROMARK® System, an advanced device that employs proprietary radiofrequency technology to create lesions that interrupt posterior nasal nerves, alleviating the symptoms of chronic rhinitis. The system is designed for Otolaryngologists, enhancing treatment precision and patient comfort, and is applicable for both newly diagnosed and chronic rhinitis patients.
Neurent Medical generates revenue through direct sales of the NEUROMARK® System and related treatment supplies to healthcare institutions and practitioners. The business operates on a B2B model where healthcare providers purchase the system as part of treatment protocols for chronic rhinitis. Revenue is derived from the sale of the device and potential ongoing partnerships for consumable supplies and training services. Neurent Medical plans to utilize the February 2026 funding to to grow sales of NEUROMARK for chronic rhinitis, support clinical studies, and develop new products.
The company also intends to explore new markets, focusing on expanding its presence in regions where the demand for chronic rhinitis treatments is growing. Specific details on upcoming product launches and market expansion dates have not been disclosed.
Current Investors
Atlantic Bridge, Fountain Healthcare Partners, Enterprise Ireland
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment
Website
www.neuromark.com
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
NEUROMARK - timeline of key events
NEUROMARK - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - |
| EBITDA (USD) | (1,955,828) | (2,350,483) | (4,331,081) | - | - | - |
| Operating Income (USD) | (1,963,183) | (2,373,536) | (4,059,380) | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - |
| NET Income (USD) | (2,180,535) | (2,746,139) | (4,680,349) | - | - | - |
| % Net Margin | - | - | - | - | - | - |
NEUROMARK - employee data
NEUROMARK - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.